Recruiting Leukemia Studies in Heidelberg
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leu...
Study of AZD9829 in CD123+ Hematological Malignancies
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematologica...
About Leukemia Clinical Trials in Heidelberg
Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.
There are currently 2 leukemia clinical trials recruiting participants in Heidelberg, VICTORIA. These studies are seeking a combined 385 participants. Research is being sponsored by Amgen, AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.
Leukemia Clinical Trials in Heidelberg — FAQ
Are there leukemia clinical trials in Heidelberg?
Yes, there are 2 leukemia clinical trials currently recruiting in Heidelberg, VICTORIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Heidelberg?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Heidelberg research site will contact you about next steps.
Are clinical trials in Heidelberg free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Heidelberg studies also compensate for your time and travel.
What leukemia treatments are being tested?
The 2 active trials in Heidelberg are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.
Data updated March 2, 2026 from ClinicalTrials.gov